MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, has hired Dr. Lori McDonald as Vice President, Quality & Compliance...
FOSS NIRSystems, Inc. is pleased to announce that Tim McCann has joined as our Mid-Atlantic Account Manager...
Silence Therapeutics plc announced changes to its Board of Directors as part of the company’s plan for growth...
Newly appointed Vice President of Medical Research at Pharmaceutical Profiles, Dr Jo Collier believes imaging is the key to early-phase efficacy studies...
Santaris Pharma A/S, announced that Søren Tulstrup, previously Vice President, Global Human Health at Merck & Co., Inc., has been appointed President & Chief Executive Officer, effective July 1, 2008...
Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announced the appointment of Damian Marron as Chief Executive Officer, effective immediately...
The CDISC European Interchange in Copenhagen saw a surge of interest this year and with that a significant increase in numbers...
ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International AB (Nordic Exchange: BINV) reported that the results from the first Phase l study of novel anti-cancer agent TB-403 showed that it is safe and well tolerated, with pharmacokinetic properties enabling it to be developed for the treatment of cancer...
T3Therapeutics, LLC and Archimedes Development Ltd, a subsidiary of Archimedes Pharma Ltd the UK-based pan-European specialty pharmaceutical company, announced positive clinical data from their Phase I study evaluating the relative bioavailability of oral modified release formulations of liothyronine sodium (T3) compared with oral immediate release T3 tablets in healthy volunteers...
VTT Technical Research Centre of Finland, GE Healthcare, a division of the General Electric Company (NYSE: GE) and a Consortium of leading research institutions across Europe announced the PredictAD project, a research collaboration aimed at developing new diagnostic procedures for patients with Alzheimer’s disease...
Results from a landmark study have shown that sunitinib (SUTENT™) has demonstrated overall survival greater than two years in patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer...
